2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now
Real Estate
The Motley Fool

2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now

July 19, 2025
04:27 AM
4 min read
AI Enhanced
investmentmoneywealthstockstradingfinancialhealthcarereal estate

Key Takeaways

From an analytical perspective, If putting your money to work on Wall Street is something you haven't started doing because it feels a rich person's game and you're not one,...

Article Overview

Quick insights and key information

Reading Time

4 min read

Estimated completion

Category

real estate

Article classification

Published

July 19, 2025

04:27 AM

Source

The Motley Fool

Original publisher

Key Topics
investmentmoneywealthstockstradingfinancialhealthcarereal estate

From an analytical perspective, If putting your money to work on Wall Street is something you haven't started doing because it feels a rich person's game and you're not one, I've got good news

Furthermore, Discount brokerages no longer charge the trading fees that made in small increments a losing position

These days, folks who invest in tiny increments are ly to receive identical returns to wealthier investors who make big trades

At the moment, anyone with $100 to spare can scoop up s of Healthpeak perties (DOC -6. 73%) and Pfizer (PFE -0

Nevertheless, Both of these stocks offer dividend yields above 6% at recent prices (which is quite significant)

On the other hand, Plus, there are good reasons to expect payout raises from these stocks in the near term

Read on to see why they look great options for everyday investors who want to grow their passive income

In contrast, Image source: Getty Images

Healthpeak perties This healthcare-related real estate investment trust (REIT) expanded last year when Physicians Realty Trust and Healthpeak combined

At the same time, Going into the merger, Healthpeak was focused on laboratories that are rented out to drugmakers of all sizes

Adding Physicians Realty Trust's portfolio of medical office buildings gave the REIT some diversification that investors appreciate

At the end of March, health systems and physician groups were responsible for 55% of annualized base rent

Drugmakers of different sizes were responsible for another 34% of annualized rent, considering recent developments

Continuing care retirement communities and various other facilities rounded out the rest of the portfolio

Nevertheless, 1% of annualized rent, HCA Healthcare, a publicly traded hospital operator, is Healthpeak's biggest tenant

Its next largest tenant, CommonSpirit Health, is responsible for 2. 9% of rental revenue (this bears monitoring)

Investors can look forward to increasing dividend payouts from Healthpeak perties stock in the near term

Furthermore, Management expects funds from operations (FFO), a xy for earnings used to evaluate REITs, to land in a range between $1, in today's market environment. 87 per this year, given the current landscape

Moreover, This's more than enough to support raising a payout currently set at an annualized $1

This demonstrates that vast majority of Healthpeak's perties are rented out under net leases that leave tenants responsible for nearly all the variable costs associated with owning its buildings, given the current landscape

Furthermore, Nevertheless, With annual rent escalators written into long-term leases, investors can reasonably expect this REIT's dividend payout to move steadily in the right direction over the long run

Meanwhile, Pfizer s of America's largest drugmaker are down by 60% from a peak they reached in 2021, in today's financial world

Additionally, The past four years have been disappointing from a principal-appreciation standpoint, but income-seeking investors are doing just fine

Pfizer's dividend payout has grown every year since 2009

However, At its beaten down price the stock offers an eye-popping 6

On the other hand, 9% dividend yield as I write this

In addition to COVID-19-related revenue that collapsed faster than expected, Pfizer stock is way down because investors are worried upcoming patent cliffs regarding top-selling medications

Investors have good reasons to be concerned Pfizer's future cash flows

Earlier this year, CEO Albert Bourla warned that market exclusivity losses would ly reduce revenue by $17 billion to $18 billion beginning in 2026 and ending in 2028

With total sales that rose to $62. 5 billion during the 12 months this March, filling the holes that exclusivity losses could punch in its income statement won't be easy

Furthermore, Luckily, the company reinvested much of its COVID-19 windfall into a ductive development pipeline, given the current landscape

In 2023, the Food and Drug Administration apved nine new medicines from Pfizer (remarkable data), in this volatile climate

In 2024, the company received over a dozen FDA apvals for both new and existing treatments

By 2030, management expects new ducts that Pfizer acquired to der $20 billion in annual revenue

That's enough to keep pushing its big needle forward despite expected losses to patent cliffs (quite telling), given current economic conditions

Nevertheless, Pfizer's $43 billion acquisition of Seagen in 2023 gave it access to several blockbuster cancer therapies

While their previous owner outsourced manufacturing, Pfizer's plan to bring manufacturing in-house could help fits expand faster than sales in the years ahead

I wouldn't expect rapid dividend payout raises from this stock in the years ahead, but steady movement in the right direction seems ly

However, Adding some s to a diversified portfolio now looks a smart move for investors who want big dividend payments that could grow even larger.